TABLE 2.
Persistence rates at 3, 6, and 12 months by individual DOACs in each database.
| Netherlands (Mondriaan) | Germany (AOK NORDWEST) | Germany (Bavarian claims) | Spain (BIFAP) | |||||||||||||||||||
| Persistence (%) | CI 95% | Number of discontinuers/number of remaining patients | Persistence (%) | CI 95% | Number of discontinuers/number of remaining patients | Persistence (%) | CI 95% | Number of discontinuers/number of remaining patients | Persistence (%) | CI 95% | Number of discontinuers/number of remaining patients | |||||||||||
| Dabigatran | ||||||||||||||||||||||
| 3m | 56 | (46–67) | 40/49 | 87 | (86–88) | 495/3,370 | NA | 83 | (82–84) | 603/2,668 | ||||||||||||
| 6m | 43 | (33–53) | 51/32 | 76 | (75–77) | 929/2,879 | NA | 74 | (72–75) | 885/2,144 | ||||||||||||
| 12m | 22 | (13 -0.32) | 64/13 | 64 | (62 -0.65) | 1,383/2,306 | NA | 62 | (60–63) | 1,217/1,518 | ||||||||||||
| Apixaban | ||||||||||||||||||||||
| 3m | 69 | (57 -0.81) | 18/32 | 83 | (82–84) | 797/3,717 | NA | 89 | (88–90) | 357/2,500 | ||||||||||||
| 6m | 49 | (34 -0.63) | 27/19 | 65 | (63–66) | 1,542/2,429 | NA | 81 | (79–82) | 571/1884 | ||||||||||||
| 12m | 32 | (16–49) | 31/6 | 46 | (44–48) | 2,138/1,158 | NA | 70 | (69–72) | 764/939 | ||||||||||||
| Rivaroxaban | ||||||||||||||||||||||
| 3m | 60 | (54–66) | 106/145 | 84 | (83–84) | 1920/9,700 | NA | 86 | (85–87) | 849/4,576 | ||||||||||||
| 6m | 51 | (45–57) | 126/99 | 69 | (68–70) | 3,566/7,559 | NA | 78 | (77–79) | 1,224/3,727 | ||||||||||||
| 12m | 43 | (36 -0.49) | 140/49 | 56 | (55–57) | 4,947/5,266 | NA | 69 | (68 -0.71) | 1,600/2,506 | ||||||||||||
| Log-rank test | pending | <0.001 | <0.001 | |||||||||||||||||||
| Spain (SIDIAP) | United Kingdom (CPRD) | France (EGB) | Denmark (DNR) | |||||||||||||||||||
| Persistence (%) | CI 95% | Number of discontinuers/number of remaining patients | Persistence (%) | CI 95% | Number of discontinuers/number of remaining patients | Persistence (%) | CI 95% | Number of discontinuers/number of remaining patients | Persistence (%) | CI 95% | Number of discontinuers/number left | |||||||||||
| Dabigatran | ||||||||||||||||||||||
| 3m | 75 | (74–76) | 1,174/3,402 | 87 | (85–89) | 147/910 | 83 | (79–86) | 73/333 | 89 | (89–90) | 2,335/18,929 | ||||||||||
| 6m | 66 | (64–67) | 1,574/2,838 | 79 | (76–81) | 226/705 | 73 | (68–77) | 111/265 | 77 | (77–78) | 4,797/14,909 | ||||||||||
| 12m | 54 | (52–55) | 2053/1982 | 70 | (67–73) | 295/463 | 61 | (56–66) | 151/187 | 62 | (61–0.63) | 7,559/10,488 | ||||||||||
| Apixaban | ||||||||||||||||||||||
| 3m | 84 | (83–86) | 409/1984 | 91 | (90–93) | 152/1,340 | 87 | (83–90) | 44/270 | 93 | (93–94) | 576/7,640 | ||||||||||
| 6m | 77 | (75–78) | 566/1,531 | 87 | (85–88) | 211/943 | 82 | (77–86) | 59/187 | 83 | (82–0.84) | 139/5,452 | ||||||||||
| 12m | 66 | (64–69) | 728/816 | 81 | (79–84) | 254/431 | 71 | (65–77) | 75/63 | 68 | (67–0.70) | 2079/2,491 | ||||||||||
| Rivaroxaban | ||||||||||||||||||||||
| 3m | 80 | (79–81) | 850/3,213 | 89 | (88–90) | 339/2,438 | 83 | (81–85) | 173/798 | 92 | (92–93) | 767/8,416 | ||||||||||
| 6m | 72 | (71–74) | 1,141/2,587 | 84 | (83–86) | 454/1716 | 76 | (73–78) | 244/647 | 82 | (81–83) | 1,618/6,023 | ||||||||||
| 12m | 62 | (60–64) | 1,453/1,634 | 78 | (76–79) | 561/856 | 67 | (64–70) | 312/451 | 64 | (64–66) | 2,678/3,338 | ||||||||||
| Log-rank test | <0.001 | <0.001 | 0.003 | <0.001 | ||||||||||||||||||